Last reviewed · How we verify
Havrix+Healive
Havrix+Healive is a combination vaccine that provides immunization against hepatitis A and hepatitis B through inactivated viral antigens.
Havrix+Healive is a combination vaccine that provides immunization against hepatitis A and hepatitis B through inactivated viral antigens. Used for Prevention of hepatitis A infection, Prevention of hepatitis B infection.
At a glance
| Generic name | Havrix+Healive |
|---|---|
| Also known as | Hepatitis A vaccine |
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | Combination inactivated viral vaccine |
| Target | Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Havrix is an inactivated hepatitis A vaccine that stimulates antibody production against hepatitis A virus. Healive is an inactivated hepatitis B vaccine containing hepatitis B surface antigen (HBsAg) that triggers immune response against hepatitis B virus. Together, the combination provides dual protection against both hepatitis A and B infections.
Approved indications
- Prevention of hepatitis A infection
- Prevention of hepatitis B infection
Common side effects
- Injection site pain or soreness
- Injection site swelling or redness
- Fever
- Fatigue
- Headache
Key clinical trials
- Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A Vaccine (PHASE4)
- Immunogenicity and Interchangeability of Two Inactivated Hepatitis A Vaccines (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |